@article{e45cb31a3e7f4f82b936e646dc7366bd,
title = "Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis",
abstract = "Alemtuzumab is an anti-CD52 monoclonal antibody used for the treatment of lymphoproliferative disorders and relapsing-remitting multiple sclerosis. We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors.",
keywords = "Acute coronary syndrome, Adverse events, Alemtuzumab, Multiple sclerosis",
author = "Romba, {Meghan C.} and Newsome, {Scott D.} and McArthur, {Justin C.}",
note = "Funding Information: Dr. Meghan C. Romba has received fellowship funding through the National MS Society . Dr. Scott D. Newsome has participated in scientific advisory boards for Biogen, Genentech, Celgene, EMD Serono and is an advisor for Gerson Lehrman Group. He has received grant/research funding (paid directly to Institution): Biogen, Genentech, Department of Defense, National MS Society , Patient Centered Outcomes Research Institute. Dr. Justin McArthur receives grant support by the National Institute of Mental Health P30MH075673 . Publisher Copyright: {\textcopyright} 2019",
year = "2019",
month = sep,
doi = "10.1016/j.msard.2019.06.022",
language = "English (US)",
volume = "34",
pages = "100--102",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier B.V.",
}